Oncotarget

Clinical Research Papers:

Preoperative blood-routine markers and prognosis of esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study

Dan Hu, Xiandong Lin, Yan Chen, Qing Chang, Gang Chen, Chao Li, Hejun Zhang, Zhaolei Cui, Binying Liang, Wenhui Jiang, Kaida Ji, Jun Huang, Feng Peng, Xiongwei Zheng and Wenquan Niu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23841-23850. https://doi.org/10.18632/oncotarget.13318

Metrics: PDF 1044 views  |   HTML 1760 views  |   ?  


Abstract

Dan Hu1,*, Xiandong Lin1,*, Yan Chen2,*, Qing Chang3,*, Gang Chen1, Chao Li1, Hejun Zhang1, Zhaolei Cui2, Binying Liang4, Wenhui Jiang1, Kaida Ji3, Jun Huang3, Feng Peng5, Xiongwei Zheng1 and Wenquan Niu3

1 Department of Pathology, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

2 Department of Clinical Laboratory, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

3 State Key Laboratory of Medical Genomics, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

4 Department of Medical Record, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

5 Department of Cardiology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

* Shared first authors

Correspondence to:

Wenquan Niu, email:

Xiongwei Zheng, email:

Feng Peng, email:

Keywords: esophageal squamous cell carcinoma; blood-routine marker; prognosis; the FIESTA study

Received: July 30, 2016 Accepted: October 14, 2016 Published: November 11, 2016

Abstract

This prospective study was designed to investigate the prognosis of preoperative blood-routine markers for esophageal cancer mortality by using data from the ongoing Fujian prospective investigation of cancer (FIESTA) study. Patients who received three-field lymphadenectomy for esophageal cancer between 2000 and 2010 were enrolled. Of 2535 patients with complete survival data, esophageal squamous cell carcinoma (ESCC) accounted for 94.5% (n = 2396). Here, only ESCC patients were analyzed, with the median follow-up time of 38.2 months (range: 0.5 to 180 months). Of 10 blood-routine markers evaluated, platelet count and red cell distribution width (RDW) were two significant predictors for ESCC mortality in men (adjusted hazard ratio or HR = 1.25 and 0.84, 95% confidence interval or CI: 1.08-1.22 and 0.75-0.93, P < 0.001 and P = 0.001, respectively), while in women only lymphocyte showed marginal significance. Based on individual results, a new derivate calculated as platelet count to RDW ratio (PRR) was created, and it was superior over other widely-evaluated derivates in men after adjustment (HR = 1.21, 95% CI: 1.13-1.30, P < 0.001), while there was no observable significance in women. In further stratified analyses, the prognosis of PRR for ESCC mortality was reinforced in men with tumor-node-metastasis stage III (HR, 95% CI, P: 1.18, 1.09-1.28, 0.001), invasion depth T3-T4 (1.17, 1.08-1.26, <0.001) or positive lymph node metastasis (1.37, 1.18-1.59, <0.001). Taken together, we created a new derivate PRR that was proven to be superior over other blood-routine markers and exhibited strong prognostic capability for ESCC mortality in Chinese men.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13318